Amid a massive reorganization of the federal healthcare infrastructure that has prompted pushback from biotech and healthcare ...

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...

After years of back-and-forth with the FDA over Hetlioz's potential use as a jet lag disorder treatment, Vanda ...

As work progresses on an up-and-coming biologics plant in North Carolina, specialty pharma company Kyowa Kirin has completed ...

Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2 ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood product specialist remains hopeful that Hemgenix is here to stay. “I hope ...

On the heels of similar investment pledges from Eli Lilly and Johnson & Johnson, Switzerland’s Novartis is stepping up to the ...

Ahead of a planned trial next month, Jazz Pharmaceuticals is moving to resolve antitrust allegations surrounding its key ...

PhRMA is again turning up the heat on both big insurance companies and their pharmacy benefit managers (PBMs) in a new ad ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...